KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Net Margin (2016 - 2025)

Pacific Biosciences Of California has reported Net Margin over the past 16 years, most recently at 90.43% for Q4 2025.

  • Quarterly results put Net Margin at 90.43% for Q4 2025, down 9647.0% from a year ago — trailing twelve months through Dec 2025 was 341.47% (down 14029.0% YoY), and the annual figure for FY2025 was 341.47%, down 14029.0%.
  • Net Margin for Q4 2025 was 90.43% at Pacific Biosciences Of California, up from 98.85% in the prior quarter.
  • Over the last five years, Net Margin for PACB hit a ceiling of 6.04% in Q4 2024 and a floor of 1146.81% in Q1 2025.
  • Median Net Margin over the past 5 years was 151.94% (2024), compared with a mean of 228.78%.
  • Peak annual rise in Net Margin hit 37583bps in 2025, while the deepest fall reached -94537bps in 2025.
  • Pacific Biosciences Of California's Net Margin stood at 192.48% in 2021, then crashed by -60bps to 308.5% in 2022, then surged by 54bps to 140.55% in 2023, then soared by 104bps to 6.04% in 2024, then plummeted by -1596bps to 90.43% in 2025.
  • The last three reported values for Net Margin were 90.43% (Q4 2025), 98.85% (Q3 2025), and 105.44% (Q2 2025) per Business Quant data.